Trial intelligence / Profile preview

Venetoclax plus azacitidine versus azacitidine in previously untreated AML patients ineligible for standard induction therapy

CTR20171498Phase 3Active

Sponsor

AbbVie Inc.

Start

Jun 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Countries

1